President & Chief Executive Officer
Mr. Ledger joined Nuvo in April 2016 as Vice President, Business Development. In this role, he was responsible for all licensing activities related to the Pennsaid franchise, while also serving as the lead on product in-licensing and corporate M&A opportunities to further enhance the company’s global business. He was appointed President of Nuvo Pharmaceuticals in November 2016 and subsequently President & CEO in November 2017. Mr. Ledger has been responsible for leading Nuvo through its evolution from a manufacturing focused business, to the diversified and global pharmaceutical company it has become.
Mr. Ledger has 15 years experience in pharmaceutical corporate and business development. Prior to joining Nuvo, he served as Vice President, Business Development & International Business at Tribute Pharmaceuticals Canada Inc. While at Tribute, Mr. Ledger was a member of the senior management team that completed six transactions with an aggregate value of over CDN$250 million, culminating in a merger with Pozen Inc. and the subsequent formation of Aralez Pharmaceuticals Inc. Prior to joining Tribute, Mr. Ledger was Director, Business Development at SteriMax Inc., a specialty pharmaceutical company focused on the commercialization of essential hospital and retail pharmacy products within Canada, where Mr. Ledger was responsible for a series of successful product acquisition and licensing transactions.
Mr. Ledger holds an honours Bachelor of Business Administration degree from Trent University and is an active member of the Canadian Healthcare Licensing Association (CHLA).